(UroToday.com) The 2024 American Urological Association (AUA) annual meeting featured a plenary session, and a presentation by Dr. Todd Morgan discussing the AUA guidelines for salvage therapy for ...

(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a session on new approaches to curing bladder and kidney cancer. Dr. Peter O'Donnell presented ...

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...

Substaging and Stratified Treatment of T1 Bladder Cancer - a Nationwide Register-Based Study. July 15, 2026 Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer ...

Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Arun Azad discussing EvoPAR-Prostate01, a phase III, double-blind, ...

(UroToday.com) The 2026 American Society of Clinical Oncology Genitourinary (ASCO) Annual Meeting held in Chicago, IL, was host to the Prostate, Testicular, and Penile Cancer - Rapid Oral Abstracts ...

ASCO 2024 Bladder Cancer ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options? ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive ...

Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...

(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured an oral abstract session on urothelial carcinoma, and a presentation by Dr. Daniel Petrylak discussing the ...

(UroToday.com) John Wei presents this year’s update on the AUA Guidelines, focusing on the Early Detection of Prostate Cancer. He concisely summarized the key new guideline recommendations. First, he ...

Beyond Lutetium PSMA: Exploring Terbium-161 for Treatment-Resistant Prostate Cancer "Presentation" - Michael Hofman Comparing PSMA-617 and PSMA-I&T Radiopharmaceuticals for Prostate Cancer Therapy ...